Select Revenue HighlightsWorldwide sales were $12.3 billion for the second quarter of 2012, an increase of 1 percent, or 5 percent excluding foreign exchange, compared with the second quarter of 2011. Sales also were unfavorably impacted by the arbitration settlement agreement with Johnson & Johnson discussed below. The following table reflects sales of the company's top pharmaceutical products, as well as total sales of animal health and consumer care products.
|$ in millions||Second Quarter 2012||Second Quarter 2011||Change|
|PROQUAD, M-M-R II and VARIVAX||316||291||9%|